Chris was diagnosed with non-Hodgkin’s lymphoma in July 2014, just before he returned to college for football camp. Chris immediately began treatment at the Children’s Cancer Institute at Hackensack University Medical Center, facing his grueling treatments with determination, courage and indomitable spirit.
He graduated college in 2017 after completing his final semesters undergoing chemotherapy treatments and dealing with side effects. This herculean effort was just the starting point for Chris who, being a rare breed, has used his experience, his skill, and his talent to help give back to his community.
While many of us would be content to be in remission, Chris decided to start training for the 2XU New York Triathlon in support of Tackle Kids Cancer. Speaking ahead of the race, Chris said,
“I will race in honor of all the friends and families I have met through Tackle Kids Cancer, especially the kids who are still undergoing treatments and those who are no longer with us today. Racing in a New York City triathlon as a Tackle Kids Cancer athlete is an opportunity for me to give back to a Foundation that has done so much for me, while having the ability to inspire other kids and families who are going through cancer treatments.”
Chris continues his fundraising efforts in conjunction with the New York Giants, and recollects just how important the outreach from players from the team was during his treatments. He said he was inspired by visits from Odell Beckham and Eli Manning, noting just how hard the team works to bring a smile to the faces of patients and their parents.
Visit the Inspiration Collection by Rare Breed $1 from every item purchased will be donated to Tackle Kids Cancer.
You can watch Chris' interview on One-on-One with Steve Adubato below:
Chris continues to support Tackle Kids Cancer and is committed to raising the profile of the organization through his charity work. Rare Breed is always inspired by outstanding young people in our community and commits to give back XXX to support Tackle Kids Cancer in 2021.